Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

 

 

Webcasts

02-28-2019

Reata Pharmaceuticals Management Call

Webcast: click here
Press (02-28-2019): Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2018 Financials and Operating Results
Press (02-21-2019): Reata to Report Fourth Quarter and Full Year 2018 Financials and to Provide an Update on Development Programs

Teleconference Information

Date: Thursday, February 28, 2019
Time: 8:00 a.m. ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 8569879

Read more

 MP3      PDF

02-20-2019

Reata Pharmaceuticals Management Call

Webcast: click here
Press: Reata Announces Positive Phase 2 Data For Bardoxolone Methyl In Patients With Focal Segmental Glomerulosclerosis And In Patients From All Four Cohorts Of Phoenix

Webcast Information

Date: Wednesday, February 20, 2019
Time: 8:00 a.m. ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Conference ID: 6555059

Read more

 MP3      PDF

01-03-2019

Reata Management Call to Discuss Phase 3 ADPKD Study Design

Webcast: click here
Press: Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Webcast Information

Date: Thursday, January 3, 2019
Time: 4:30 p.m. ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Conference ID: 8078409

Read more

 MP3      PDF

Events and Presentations

03-05-2019

Corporate Presentation

 PDF

10-18-2018

October 2018

The following posters were presented at the American Society of Nephrology Kidney Week 2018 Annual Meeting in San Diego, California:

Geoffrey A. Block, M.D., CCRI, Director of Clinical Research at Denver Nephrology, presented One-Year Data Report from “CARDINAL”: A Phase 2/3 Study of Bardoxolone Methyl in Patients with Alport Syndrome.

Geoffrey A. Block, M.D., CCRI, Director of Clinical Research at Denver Nephrology, presented Analyses from a Phase 2 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with IgA Nephropathy: The PHOENIX Study.

Pablo Pergola, M.D., Ph.D., Research Director at Renal Associates PA in San Antonio, TX, presented Analyses from a Phase 2 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease: The PHOENIX Study.

Arnold L. Silva, M.D., Ph.D., Director of Clinical Research at Boise Kidney and Hypertension Institute, presented Analyses from a Phase 2 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Type 1 Diabetes: The PHOENIX Study.

Click the PDF link to view or download a PDF of these posters.

Read more

 PDF

07-23-2018

July, 2018

  • Statistically significant improvement in kidney function maintained in Alport syndrome patients after 48 weeks of treatment
  • Statistically significant retained benefit of 4.1 ml/min in Alport syndrome patients following 48 weeks of treatment and 4 weeks of drug withdrawal
  • Statistically significant improvement in kidney function observed in ADPKD patients after 12 weeks of treatment

Click the PDF link to read the full press release.

Read more

 PDF

07-23-2018

Webcast: Management Call to Discuss Phase 2 CARDINAL and PHOENIX Updates, July 2018

 MP3       PDF

05-26-2018

May 2018
Professor Peter Rossing, MD, DMSc, presented the poster: Decreases in Weight with Bardoxolone Methyl in Obese Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes – Post-Hoc Analyses from BEACON, at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Copenhagen, Denmark 2018.

Read more

 PDF